The overarching goal of this review is to highlight the current progress of immunotherapy in pancreatic 3 cancer. Despite all the efforts, pancreatic cancer remains a disease that is refractory to almost all 4 therapies and immunotherapy for pancreatic cancer remains in its infancy. In this review, we summarize 5 promising advances and major hurdles in developing immunotherapeutic strategies for pancreatic cancer 6 as presented in recent publications and a clinical trial database. Notably, a combination regimen of 7 chemotherapy followed by immunotherapy appears to be superior to chemotherapy alone, wherein 8 chemotherapeutic agents may play a dual role by reducing overall tumor burden through direct killing of 9 cancerous cells and by indirect release of pro-inflammatory molecules and tumor associated antigens 10 which, when presented in an immunogenic fashion, may function as an in situ "vaccine". Critically, the 11 timing of administration of standard chemotherapy can markedly impact the induction of antitumor 12 responses We anticipate that among the gamut of combination immunotherapy and chemo-radiation 13 therapies that are now being evaluated, we will eventually be able to optimize a regimen that can 14 generate long-lasting responses and usher a new weapon in the fight against pancreatic cancer. 15 16
Introduction 1
Immunotherapy has emerged as a pillar (1) in cancer treatment through its gradual acceptance as 2 standard of care for some liquid and solid tumor malignancies, such as: B cell leukemia (2), metastatic 3 melanoma (3, 4) and Non-Small-Cell Lung Cancer (NSCLC) (5, 6), joining the ranks of conventional 4 modalities such as surgery, chemo/radiation, and targeted therapies. While this era has witnessed 5 remarkable success in immune-based therapies for B cell malignancies as well as more limited effects 6 on solid tumor malignancies such as melanoma and NSCLC, advanced pancreatic cancer is a disease 7 that remains refractory to almost all the therapies (7, 8). However evidence of success in other solid 8 tumors and a renaissance in our understanding of pancreatic tumor biology has led to translational 9 efforts to pioneer immune-based approaches for the treatment of pancreatic cancer that has been 10 accompanied by significant progress in the field (9). 11
12
Here, we present a review of the literature and clinical databases, highlighting promising advances and 13 major hurdles in immunotherapy of pancreatic cancer, in the hope that it may provide insight into 14 potential combination immune-based strategies and a rational therapeutic window within which these 15 approaches may be most effective. 16
17

Current therapies against pancreatic cancer 18
Pancreatic cancer is a devastating and almost uniformly lethal malignancy, notoriously resistant to most 19 therapies. Over 90% of pancreatic cancers present as pancreatic ductal adenocarcinoma (PDAC). In 20 2015, ~48,960 people in the United States will be diagnosed with this disease (10). Because of the 21 aggressive nature of this cancer, the annual mortality rates closely match the incidence rate, and it is 22 expected that ~40,000 will die from PDAC in the same year, with a 6% 5-year survival rate. For the 23 20% of patients with disease involving only the pancreas, surgical resection is the primary therapy. In 24 the ~80% of patients with regional disease extension or metastases at presentation, chemotherapy is the 25 primary treatment (11). Among the therapeutic options, polychemotherapy with infusional 5-26 fluorouracil (5-FU), leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) or gemcitabine plus 27 albumin-bound paclitaxel (nab paclitaxel) are commonly employed (11). Nab-paclitaxel is a cytotoxic 28 agent that binds to overexpressed SPARC (Secreted Protein Acidic and Rich in Cysteine) in cancer cells 29 and stroma in the PDAC tumor microenvironment (TME), thus increasing drug delivery and 1 accumulation in tumor cells. As compared to gemcitabine alone, nab-paclitaxel plus gemcitabine 2 significantly improved overall survival, progression-free survival, and response rate in metastatic 3 PDAC, but rates of peripheral neuropathy and myelosuppression were increased (12). However, 4 because of the inherent chemoresistance of PDAC, median progression-free survival (PFS) with these 5 intensive regimens is ≤ 6 months (12, 13). Approximately 45% of patients who receive such first-line 6 regimens are alive and sufficiently fit to receive second-line therapy (12, 13), but only a few therapies 7 have been approved by the Food and Drug Administration (FDA) for such patients. On October 22, 8 2015 the U.S. FDA approved Onivyde (irinotecan liposome injection), in combination with fluorouracil 9 and leucovorin, to treat patients with advanced (metastatic) pancreatic cancer who have been previously 10 treated with gemcitabine-based chemotherapy. Onivyde represented a nanotherapeutic version of 11 chemotherapy that directly delivers the agent to the tumor microenvironment and prolongs the active 12 drug uptake. Recent results from these pilot studies demonstrated promise for pancreatic cancer with 13 increased median survival for 2 months (14). Despite off-label use of existing chemotherapeutic agents, 14 survival at 2 years is < 10%. Thus, while antitumor benefit has been observed with such regimens, 15 toxicity is substantial and therapeutic options are limited. Novel, less toxic approaches are desperately 16 needed for this lethal cancer, particularly in patients who experience failure of existing first-line 17 therapies. Despite these efforts, the best supportive care and treatment regimens for patients with 18 pancreatic cancer can only prolong survival for a few months, with the goal of achieving palliation 19 rather than cure (15) . 20 
21
Tumor microenvironment (TME) is a barrier to immune infiltration in pancreatic cancer 22
In the multistep progression of PDAC, the emergence of initiating genetic events within neoplastic cells, 23 such as oncogenic KRAS mutations, is subsequently sculpted by additional pressures in the TME, 24 including co-opting of the innate and adaptive arms of the host immune system (16). The importance of 25 the TME in the biology of this disease, as well as a potential substrate for therapy, has become 26 increasingly recognized (17-19). PDAC exists in a complex desmoplastic stroma that provides a 27 structural framework for tumor growth, and conceals the tumor cells from immune surveillance. Tumor-28 associated stroma comprises a mix of fibroblasts (myofibroblasts and pancreatic stellate cells) and an 29 abundance of immunosuppressive regulatory T cells (Tregs), myeloid derived suppressor cells 30 (MDSCs), tumor-associated macrophages (TAMs) and mast cells (20-22) that restrain immunologically-1 mediated tumor cell killing (23) . PDAC cells secrete chemokines that recruit this myriad of immune 2 suppressor cells to the TME, which are then activated either by direct contact, or by cancer cell-derived 3 triggers to selectively release additional tumor-promoting mediators (17, 20) . In preclinical models, 4 genetic or pharmacological modulation of either the number, or function, of immune suppressor cells in 5 the TME has been shown to decrease the growth of PDAC (24-26). However, none of these approaches 6 have yet made their way into the clinic, and therefore, single-agent immunotherapy approaches 7 attempted to date, such as checkpoint inhibitors or vaccines, have been at best modestly successful (27-8 33) . In contradistinction to melanoma, PDAC has long been considered a "non-immunogenic" 9 neoplasm, in part due to the formidable barrier of the TME. Converting a non-immunogenic PDAC into 10 an "immunogenic" neoplasm may create a treatment window for judicious application of 11 immunotherapeutic strategies (30, 34, 35) . 12
13
Current strategies in cancer immunotherapy 14
With great strides in the understanding of immunology and cancer biology over the past 20 years, cancer 15 immunotherapy has emerged as a model for successfully translating scientific discovery from the 16 laboratory to the clinical arena. Effective immunotherapies have mediated durable antitumor immune 17 response and cancer regressions, leading to remarkable prolongation in the survival of patients with 18 leukemia, melanoma, lung cancer, liver, bladder, ovarian, renal, and prostate cancers (36). On the heels 19 of these studies, immunotherapy may be poised to revolutionize in similar fashion the treatment of 20 pancreatic cancer. We summarize below the current immunotherapeutic strategies for human cancers in 21 other regimens, such as chemo/radiotherapy, checkpoint control antibodies were introduced to the trials 14 to maximize the efficacy. GVAX in conjunction with immunomodulatory cyclophosphamide (54) has 15 been applied to many preclinical tumor models and several human cancers as the low dose 16 cyclophosphamide serves as a vaccine enhancer in disrupting immune tolerance through depleting 17 regulatory T cell in situ and promoting dendritic cell maturation. Indeed, heterologous prime/boost with 18 GVAX and CRS-207 in pancreatic patients conditioned with cyclophosphamide extended survival with 19 minimal toxicity (28). Recent trials involving this combinational vaccine approach are listed in Table 3 . loss. This vaccination protocol has proven to be safe and well tolerated (60) with some significant 7 response, as indicated in Table 5 . 8 Table 5 . CEA/MUC-1 clinical trials* against pancreatic cancer 9 Table 6 reflect improved survival in patients when compared with a historical control 12 (62) in phase II studies which remain to be proven in randomized Phase III trials (currently accruing). 13 Table 6 . Algenpantucel-L clinical trials* against pancreatic cancer 14 The first clinically approved use of ibrutinib, a novel BTK inhibitor developed by Pharmacyclics has led 4 to decreased mouse tumor growth and improved responsiveness to gemcitabine in orthotopic pancreatic 5 cancer mouse models (64). In another preclinical study, Ibrutinib improved the survival of both 6
genetically engineered PDAC models, as well as mice bearing patient-derived PDAC xenografts (65). 7
Ibrutinib therapy also reduced the stromal desmoplasia in preclinical models, and improved delivery of 8 chemotherapeutics to the tumor milieu. Inhibiting BTK has the desired effect of inhibiting mast cell 9 degranulation and cytokine secretion, a result that, our group and others have shown, mediates tumor 10 suppression in PDAC (20-22). However, Ibrutinib suffers from multiple off-target effects that limit its 11 application in solid tumors where enhancing effector T-cell function is a crucial intent (2). Ibrutinib's 12 potency on ITK (IL2-inducible T-cell kinase) and TXK (Tyrosine-protein Kinase) may explain why it 13 interferes with cell-mediated anti-tumor activities and immune-mediated killing in the TME. in Table 8 are being tested in patients with pancreatic cancer. Tremelimumab (82) anti-CTLA-4 IgG2 20 antibody achieved survival benefit for 9 patients with pancreatic cancer when combined with 21 gemcitabine in a phase I trial, and its subsequent combination regimens were under the trials in Table 8 . (tumor infiltrating lymphocytes, TIL or peripheral blood) or a genetically modified lymphocyte 10 population engineered to recognize tumor antigen through expression of the cognate chimeric antibody 11 or T-cell receptor (CAR/TCR, see Table 11 ). 12
Tumor Infiltrating Lymphocyte (TIL) 14
To date, only TIL therapies have been reported for the treatment of pancreatic cancer, as shown in Table  15 10, although efforts are underway in our lab and others to explore the use of MS/MS and RNAseq 16 analysis of patient tumor immunopeptidome to develop T cell therapy targeting autologous tumor neo-17 epitopes for pancreatic cancer. an important modality with the promise of off-the shelf strategies for the treatment of pancreatic cancer. 7
The following clinical trials in Table 12 and T-cell response in those patients indicated antimesothelin immunity and offered potential therapy 7 against pancreatic cancer. In addition to mesothelin vaccine trials using GVAX and CRS-207 in 8 combination (28), antibodies (90) against mesothelin provide an alternative for pancreatic cancer 9 immunotherapy, as shown in Table 13 . cytokine release (92). In addition to the vaccine related studies listed in the above tables, we list a broad 6 spectrum of DC vaccine trials in Table 14 . In addition to shaping the specificity of response against 7 tumor antigens through DC vaccination, these trials also focus on modifying the function and activation 8 of dendritic cells. In the immune-privileged microenvironment of pancreatic cancer, insufficiency of 9 dendritic cells is the main roadblock for T cell activation, a typical malfunction observed in many other 10 cancer types (93). Dendritic cell expansion and maturation may overcome the resistance to checkpoint 11 immunotherapy and reprogram the TME to an immunogenic microenvironment (93). paclitaxel plus gemcitabine has significantly improved overall survival, progression-free survival, and 5 response rate in patients with metastatic pancreatic adenocarcinoma as compared with gemcitabine alone 6 (12). Unfortunately, the improved median survival is only 8.5 months. The strength of combination 7 with chemotherapy and immunotherapy is being tested in animal models. 8 9 It has been recognized that an optimized approach combining anti-cancer vaccination with 10 chemotherapy and/or radiation therapy is urgently needed. The use of vaccines is also a compelling 11 approach for maintenance therapy of patients who are grossly disease-free, or whose disease is at least 12 stabilized, upon chemotherapy and/or radiation therapy. Prime-boost vaccination strategies, in particular 13 those that use Listeria vaccines for boosting, are a promising approach for maintenance therapy (100). 14 15
In preclinical studies, combination therapy of chemotherapy followed by immunotherapy is superior to 16 chemotherapy alone. In these in vivo tests, chemotherapeutic agents played a dual role. On one hand, 17 they reduced overall tumor burden by direct killing of cancer cells; on the other hand, they indirectly 18 lead to the release of pro-inflammatory molecules and tumor associated antigens (101), which may be 19 functioning as a "vaccine" by presumably releasing tumor antigens in an immunogenic fashion. This 20 may potentially explain the improved efficacy of CD40 agonists when given after, but not before, 21 chemotherapy (102). This synergistic efficacy is also observed with combined chemotherapy using anti-22 The most recent advancement of radiation technology, including intensity modulated radiation therapy, 9 stereotactic radiosurgery, proton therapy, antibody-radionuclide conjugates, has been applied to cancer 10 therapy for 20 years (104). Radiotherapy is based on the ionizing energy causing DNA damage to 11 induce direct tumor cell death, such as apoptosis, mitotic catastrophe, or necrosis, along with the cascade 12 events in tumor microenvironment (TME) (105). The best efficacy of radiotherapy will not only rely on 13 the direct tumor cell death, but also the contribution of intrinsic anti-tumor immune response. The 14 damage-associated molecular patterns in TME trigger immune sensors such as toll-like receptors (TLR) 15 and anti-PD-1 therapy is confirmed in preclinical melanoma models, although the mechanism of TCR 26 repertoire diversity and tumor heterogeneity remains unknown. In the near future, it might be possible 27 that radiation can turn pancreatic cancer from an immune privileged tumor microenvironment to an 28 immune active state. Radioimmunotherapy (110) for pancreatic cancer may emerge as a novel regimen 29 (111) complementing to the multimodality tumor directed therapy. 30
Perspectives and Conclusion 1 2
The principal goal of this review is to highlight current progress of immunotherapy in pancreatic cancer. 3 The seminal advantages that immunotherapy bring to the treatment of pancreatic cancers are: (1) The 4 ability to broaden and encompass greater numbers of patients eligible for treatment and to achieve a 5 personalized approach to medicine by using the autologous cancer antigens as a means of generating a 6 populations antigen-specific effector cells. 
